Avantor, Inc. (AVTR)
NYSE: AVTR · Real-Time Price · USD
12.09
+0.11 (0.88%)
May 7, 2025, 9:53 AM EDT - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Laboratory Solutions | 4.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Laboratory Solutions Growth | -2.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bioscience Production | 2.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bioscience Production Growth | -2.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Materials & Consumables | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Proprietary Materials & Consumables Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Third Party Materials & Consumables | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Third Party Materials & Consumables Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Services & Specialty Procurement | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Services & Specialty Procurement Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Equipment & Instrumentation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Equipment & Instrumentation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2018 |
| Americas Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2018 |
| Americas Adjusted EBITDA |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Adjusted EBITDA Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Adjusted EBITDA |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Adjusted EBITDA Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA Adjusted EBITDA |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA Adjusted EBITDA Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2018 |
| Americas |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AMEA Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Laboratory Solutions Adjusted Operating Income | 598.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Laboratory Solutions Adjusted Operating Income Growth | -6.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bioscience Production Adjusted Operating Income | 558.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Bioscience Production Adjusted Operating Income Growth | 13.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted Operating Income | -66.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted Operating Income Growth | 18.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|